Phase 2 Progressive Multiple Sclerosis Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Progressive Multiple Sclerosis
Hoffmann-La Roche360 enrolled73 locationsNCT07282574
Recruiting
Phase 1Phase 2
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis (MS) Primary ProgressiveMultiple Sclerosis (MS) Secondary Progressive+2 more
Tr1X, Inc.39 enrolled2 locationsNCT07477639
Recruiting
Phase 2
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
Secondary-progressive Multiple Sclerosis (SPMS)
Cairo University46 enrolled1 locationNCT06599307
Recruiting
Phase 1Phase 2
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Progressive Multiple Sclerosis
Novartis Pharmaceuticals28 enrolled17 locationsNCT06675864
Recruiting
Phase 2
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD54 enrolled7 locationsNCT06292923
Recruiting
Phase 2
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD55 enrolled1 locationNCT06890923
Recruiting
Phase 2
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
Multiple SclerosisProgressive Multiple Sclerosis
Haukeland University Hospital300 enrolled1 locationNCT05740722